Tom Kähler

DSB SOV engages in the provision of passenger train solutions. It offers urban, intercity, regional, and international passenger rail services. The company was founded on December 30, 1998 and is headquartered in Taastrup, Denmark.

Part of Dr. Rentschler Holding GmbH & Co. KG, Rentschler Biotechnologie Beteiligungs GmbH is a German company that provides investment services. The company is based in Laupheim, Germany. The CEOs of the company are Jürgen Müller, Nikolaus Friedrich Rentschler.

Propel Bio Partners LLC (Propel Bio Partners) is a venture capital firm founded in 2022 by Leen Kawas and Richard Alan Kayne. The firm is headquartered in Los Angeles, California.

Sosina Exploration Ltd. provides oil and gas extraction services. It operates potential oil and gas accumulations in cooperation with partners within the oil and gas industry. The company was founded in 2004 and is headquartered in London, the United Kingdom.

Odense Staalskibsværft AS engages in ship building activities. It operates machinery. The company was founded in 1918 and is headquartered in Copenhagen, Denmark.

Hottinger Brüel & Kjær A/S manufactures and distributes sound and vibration measuring equipment. It offers analysis software, pulse analyzer platform, measurement front-ends, transducers, hand-held instruments, environment management solutions, and calibration systems. The company was founded by Per V. Brüel and Viggo Kjær on November 28, 1942 and is headquartered in Naerum, Denmark.

MetriCorr ApS provides solutions, services, and products within the field of industrial corrosion risk assessment, management, and monitoring. Its products include data loggers, test stations and junction boxes, remote monitoring, webservice, and tank bottom probes. The company was founded by Lars Vendelbo Nielsen in 2002 and is headquartered in Glostrup, Denmark.

Det Kongelige Teater is a national theater in Denmark that offers a variety of performances including operas, plays, and concerts suitable for the whole family. The private company is based in Copenhagen, Denmark. Visitors can purchase tickets and learn more about the performances on the Danish company's website.

DA Invest og Udvikling A/S operates as an investment firm. It offers investment services. The company was founded in 1990 and is headquartered in Copenhagen, Denmark.

Mogens Balslev's Fond provides financial support for its subsidiary. The firm offers economic assistance to Danish engineering sciences and grants scholarships for engineering students and educational institutions. In addition, it gives support to other non-profit community. The company was founded on October 16, 1999 and is headquartered in Glostrup, Denmark.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.